Hope and help for your gastroparesis patients
Gastroparesis can be a frustrating condition to treat. But with Enterra® Therapy, you can offer a minimally invasive, advanced treatment option in your patient’s journey to relief from nausea and vomiting.
Target your patients’ nausea and vomiting symptoms
Enterra Therapy is the first and only device designed to reduce the nausea and vomiting associated with diabetic or idiopathic gastroparesis through gastric electrical stimulation (GES). It is FDA approved as a Humanitarian Device and supported by AGA and ACG guidelines.
Long-term studies show significant improvement in nausea and vomiting symptoms
Reduction in
median weekly vomiting1,2
87%
among idiopathic patients
Idiopathic group:
N=18, P<0.001
12 month follow-up
68%
among diabetic patients
Diabetic group:
N=36, P<0.001
12 month follow-up
Recommending the right patients for Enterra® Therapy
Enterra Therapy may be appropriate for patients who meet the following criteria:
- Have gastroparesis caused by diabetic or idiopathic origin
- Have difficulty managing nausea and vomiting symptoms, despite having tried first-line therapies of diet modification and medications
- Are 18-70 of age
Find an implanter or GI specialist
More than 250 of the nation’s top medical centers implant Enterra Therapy.
If you have a patient who may be a candidate for receiving Enterra Therapy, use this tool to find a trained implanter or GI specialist in your area.
- McCallum RW, Sarosiek I, Parkman HP, Snape W, Brody F, Wo J, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterol Motil. 2013 Oct;25(10):815-e636.
- McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8(11):947-e116. doi:10.1016/j.cgh.2010.05.020.
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?